pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 30·1 min read
save

Ipsen says €2 billion cash reserves give it firepower for more M&A

Jul 30, 2026·read at Endpoints ↗DealPositive

Ipsen's CFO Aymeric Le Chatelier said the company ended June with €2 billion in cash, which it describes as "firepower" for acquisitions.

The cash position gives the French biotech firm flexibility to pursue additional M&A opportunities, according to the executive.

The statement signals that Ipsen may look to expand its portfolio in the near term, though no specific targets were disclosed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Ipsen has 'firepower' for more deals with €2B war chest”

read at Endpoints ↗
86 words · retrieved Jul 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
IPSEN7

related stories

  • 14h agoRegeneron to challenge Ipsen as FDA clears bone disease drugBioPharma Dive
  • 17h agoRegeneron wins FDA approval to challenge Ipsen for rare bone disease marketBioSpace
  • 3d agoSlate, Fulcrum to combine in reverse mergerBioPharma Dive
  • 6d ago‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryFierce Biotech
  • Jul 24Ipsen’s Bylvay fails key trial in children with rare liver diseaseEndpoints